Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa)<\/a> ha participado en la publicaci\u00f3n de un estudio en el que se analizan los determinantes epigen\u00e9ticos de un fenotipo inmunoevasivo en el c\u00e1ncer de mama triple negativo HER2 bajo.<\/p>","protected":false},"excerpt":{"rendered":"El Laboratorio de Epigen\u00e9tica del C\u00e1ncer del\u00a0Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa) ha participado en la publicaci\u00f3n de un estudio en el que se analizan los determinantes epigen\u00e9ticos de un fenotipo inmunoevasivo en el c\u00e1ncer de mama triple negativo HER2 bajo.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-190762","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"\n
Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo\" \/>\n<meta property=\"og:description\" content=\"El Laboratorio de Epigen\u00e9tica del C\u00e1ncer del\u00a0Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa) ha participado en la publicaci\u00f3n de un estudio en el que se analizan los determinantes epigen\u00e9ticos de un fenotipo inmunoevasivo en el c\u00e1ncer de mama triple negativo HER2 bajo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-13T07:17:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo\",\"datePublished\":\"2025-12-13T07:17:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/\"},\"wordCount\":58,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/cc\\\/cc-epr1029.jpg\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/\",\"name\":\"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/cc\\\/cc-epr1029.jpg\",\"datePublished\":\"2025-12-13T07:17:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/cc\\\/cc-epr1029.jpg\",\"contentUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/cc\\\/cc-epr1029.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/","og_locale":"es_ES","og_type":"article","og_title":"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo","og_description":"El Laboratorio de Epigen\u00e9tica del C\u00e1ncer del\u00a0Instituto de Investigaci\u00f3n Sanitaria Illes Balears (IdISBa) ha participado en la publicaci\u00f3n de un estudio en el que se analizan los determinantes epigen\u00e9ticos de un fenotipo inmunoevasivo en el c\u00e1ncer de mama triple negativo HER2 bajo.","og_url":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/","og_site_name":"bip4ex","article_published_time":"2025-12-13T07:17:16+00:00","og_image":[{"url":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg","type":"","width":"","height":""}],"author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo","datePublished":"2025-12-13T07:17:16+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/"},"wordCount":58,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg","articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/","url":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/","name":"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#primaryimage"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg","datePublished":"2025-12-13T07:17:16+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#primaryimage","url":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg","contentUrl":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/epigenetica-e-inmunoevasion-en-cmtn-her2-bajo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Epigen\u00e9tica e inmunoevasi\u00f3n en CMTN HER2 bajo"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/190762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=190762"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/190762\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=190762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=190762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=190762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![](\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1029.jpg\")
<\/p>\n